Wolpert E, Franksson L, Kärre K
Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.
Int Immunol. 1995 Jun;7(6):919-28. doi: 10.1093/intimm/7.6.919.
T cell responses against complex antigens are often directed against a limited set of immunodominant determinants. We have studied this phenomenon at the level of cellularly processed peptides recognized by CTL in the B6 anti-BALB.B minor histocompatibility (H) barrier, comprising at least 29 antigen loci. B6 anti-BALB.B CTL always recognized three reverse phase HPLC fractions in BALB.B eluates, whether the latter were obtained from cell lysates or immunoaffinity purified class I molecules. One of these immunodominant epitopes (termed IDE-1) was H-2Db restricted, and two (termed IDE-2 and IDE-3) were H-2Kb restricted. B6 mice were immunized with spleen cells from B6 congenic mice carrying single minor H loci from BALB.B with the aim to assign IDE to given minor H loci and to investigate whether additional epitopes could be identified in the absence of the immunodominant ones. IDE-3 was found to be associated to the locus H-28; in addition five so called cryptic epitopes were defined. Induction of CTL against these epitopes required immunization with cells of the congenic strain; BALB.B spleen cells failed to immunize. One subgroup of these epitopes (those associated to H-8, H-19 and H-25) were nevertheless found to be processed and loaded in class I molecules of BALB.B cells, while there was no evidence for this for H-35 and H-36. For 10 additional congenic strains, no CTL response was detected. The results are discussed in relation to the genetic and molecular basis of minor H antigens, and mechanisms for epitope dominance operating at the level of the APC or responding T cells.
针对复杂抗原的T细胞反应通常针对一组有限的免疫显性决定簇。我们在B6抗BALB.B次要组织相容性(H)屏障中CTL识别的细胞处理肽水平上研究了这一现象,该屏障包含至少29个抗原位点。B6抗BALB.B CTL总是在BALB.B洗脱物中识别出三个反相高效液相色谱馏分,无论后者是从细胞裂解物中获得还是从免疫亲和纯化的I类分子中获得。其中一个免疫显性表位(称为IDE-1)受H-2Db限制,另外两个(称为IDE-2和IDE-3)受H-2Kb限制。用携带来自BALB.B的单个次要H位点的B6同基因小鼠的脾细胞免疫B6小鼠,目的是将IDE分配到给定的次要H位点,并研究在没有免疫显性表位的情况下是否可以鉴定出其他表位。发现IDE-3与H-28位点相关;此外,还定义了五个所谓的隐蔽表位。针对这些表位诱导CTL需要用同基因品系的细胞进行免疫;BALB.B脾细胞无法进行免疫。然而,发现这些表位的一个亚组(与H-8、H-19和H-25相关的那些)在BALB.B细胞的I类分子中被加工和装载,而对于H-35和H-36则没有证据。对于另外10个同基因品系,未检测到CTL反应。我们结合次要H抗原的遗传和分子基础以及在抗原呈递细胞或反应性T细胞水平上起作用的表位优势机制对结果进行了讨论。